PDCD1 and cutaneous melanoma: In an early study in patients who have failed prior anti-PD-1 therapy, RP2 in combination with nivolumab demonstrated an ORR of 44.4% (four out of nine) in cutaneous melanoma, 25.0% (two out of eight) in uveal melanoma, and 33.3% (one out of three) in SCCHN.58